Efficient Detection of Oligodendroglioma With 1p/19q Codeletion Mutation via Methionine PET Imaging: A Promising Diagnostic Approach.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Background Oligodendrogliomas are a distinct subtype of gliomas frequently characterized by the 1p/19q codeletion and isocitrate dehydrogenase (IDH) gene mutations, both associated with improved therapeutic response and prolonged survival. These genetic alterations modulate the transsulfuration pathway, leading to increased methionine uptake by tumor cells. Positron emission tomography (PET) with 11C-labeled methionine (MET PET) leverages these metabolic changes, providing a noninvasive means to distinguish oligodendrogliomas and predict the 1p/19q codeletion presence. This study evaluates the diagnostic potential of MET PET in detecting 1p/19q deletions and quantifying SUV max (maximum standardized uptake value) to evaluate metabolic activity in newly diagnosed oligodendrogliomas, emphasizing the value of advanced imaging in guiding targeted clinical management. Methods We performed a retrospective chart review of pediatric and adult patients treated between 1999 and 2010, a period selected to capture evolving clinical protocols and advancements in imaging techniques. This timeframe maximized data availability and provided a longitudinal perspective on how shifts in diagnostic and therapeutic strategies may have influenced outcomes. All participants underwent MET PET scans and subsequent oligodendroglioma resections, with follow-up data extending until 2010. Relevant information, including demographics, clinical details, and glioma-specific mutations, was extracted from clinical records. Cases without histological confirmation or missing genetic results (1p/19q codeletion, IDH) were excluded to safeguard data integrity and limit bias. Both univariate and multivariate linear regression analyses were employed to assess the relationship between MET PET findings (SUV max) and these genetic alterations, aiming to clarify the predictive value of PET imaging in tumor genetics. Results Among the 85 oligodendroglioma patients analyzed (median age 50 ± 3 years), 47.1% (n = 40) harbored the 1p/19q codeletion, whereas 52.9% (n = 45) did not. The median SUV max was significantly higher in patients lacking the codeletion (3.7, IQR: 2.9-4.4) than in those with it (2.2, IQR: 1.8-2.6; p < 0.001). A Mann-Whitney U test confirmed the discrepancy (U = 189, z = -6.261, p < 0.0001). Further analysis using a multiple linear regression model indicated that the absence of the 1p/19q codeletion and an elevated Ki-67 index collectively predicted higher SUV max (F(1, 82) = 10.43, p < 0.0001), accounting for approximately 42.2% of the variability in SUV max. Conclusions The findings from this study underscore the utility of the MET PET scan not only as a diagnostic tool for identifying the presence of the 1p/19q deletion in patients with oligodendrogliomas but also for evaluating tumor metabolism through SUV max measurements. The scan's ability to distinguish tumor from necrosis based on metabolic activity enhances its clinical value, providing critical insights for optimal patient management. The data suggest that patients with higher SUV max are more likely to lack the 1p/19q deletion, a finding that could significantly influence treatment decisions and prognostic assessments. Given these results, MET PET scans represent a potent tool in refining diagnostic and follow-up strategies for oligodendroglioma, guiding more targeted and effective therapeutic approaches.